Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruth Poole

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
The Health Service Journal|October 18, 2011
Community services. A fitting focus on managing dementiaRuth Poole
British Journal of Community Nursing|July 15, 2009
Partnership working with independent providersRuth Poole, Chris Wallis
Clinical Endocrinology|April 23, 2002
An audit of adult women with Turner's syndrome--is surveillance for comorbidity adequate?Ruth Poole, Brian Leatherdale
Hormones (Athens, Greece)|July 5, 2016
A case of multiple immune toxicities from Ipilimumab and pembrolizumab treatmentMalik Asif Humayun, Ruth Poole
Antimicrobial Agents and Chemotherapy|May 6, 2009
Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteersMartin Bitzan, Ruth Poole, Mariam Mehran, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
The Health Service Journal|October 18, 2011
Community services. A fitting focus on managing dementiaRuth Poole
British Journal of Community Nursing|July 15, 2009
Partnership working with independent providersRuth Poole, Chris Wallis
Clinical Endocrinology|April 23, 2002
An audit of adult women with Turner's syndrome--is surveillance for comorbidity adequate?Ruth Poole, Brian Leatherdale
Hormones (Athens, Greece)|July 5, 2016
A case of multiple immune toxicities from Ipilimumab and pembrolizumab treatmentMalik Asif Humayun, Ruth Poole
Antimicrobial Agents and Chemotherapy|May 6, 2009
Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteersMartin Bitzan, Ruth Poole, Mariam Mehran, et al.
Pageof 1